Your session is about to expire
← Back to Search
Olaparib for Prostate Cancer
Study Summary
This trial will compare olaparib and durvalumab to the standard of care for treating prostate cancer.
- Prostate Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 154 Patients • NCT02184195Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are we still able to sign patients up for this research project?
"From what is publicly available on clinicaltrials.gov, this study isn't recruiting patients at the moment. The listing for this trial was created on March 7th, 2019 and last updated on March 30th, 2020. There are 1865 other trials that are actively looking for participants though."
What sets this research apart from other similar projects?
"Olaparib has a long clinical history, with the first trial being conducted in 2005. Since then, there have been 498 active trials in locations as varied as 1844 cities and 65 countries."
How many people have signed up to participate in this experiment?
"Right now, this particular trial isn't screening for new patients. It was originally posted on March 7th, 2019 and most recently updated on March 30th, 2022. For individuals still looking to participate in research studies, there are 1367 prostate cancer trials and 498 Olaparib investigations actively admitting patients."
Is this clinical trial exclusive to the United States or are other countries involved as well?
"11 hospitals are recruiting patients for this trial, some of which include Memoral Sloan Kettering Basking Ridge in Basking Ridge, Memoral Sloan Kettering Westchester in Harrison, and Memorial Sloan - Kettering Cancer Center in New york."
What is the approved indication for Olaparib?
"Olaparib is often used to manage patients with cancer. Additionally, this medication can be given to those suffering from primary peritoneal cancer and those with advance directives."
Are there any short-term dangers associated with Olaparib?
"Olaparib has received a score of 2 from our team at Power. This is because, although there is some evidence attesting to its safety, there are no Phase 2 trials demonstrating the efficacy of Olaparib."
What are some other clinical studies that have used Olaparib?
"Olaparib's clinical trials started in 2005 at Research Site. So far, there have been a total of 165 completed studies. There are 498 active clinical trials as of now, with a large number of these based in Basking Ridge, New jersey."
Share this study with friends
Copy Link
Messenger